Axsome Therapeutics, Inc. (AXSM) said, based on preliminary financial information, Axsome expects total product revenue to be approximately $196.0 million for the fourth quarter, representing 65% annual growth compared to the fourth quarter 2024. The company expects total product revenue of approximately $638.5 million for the full year 2025, representing 66% annual growth compared to the full year 2024.
The company noted that AUVELITY net product sales are expected to be approximately $155.1 million and $507.1 million for the fourth quarter and full year 2025, respectively.
For comments and feedback contact: editorial@rttnews.com
Business News
January 09, 2026 15:02 ET U.S. external trade data and labor market figures were in focus this week as the news flow gained momentum in the new year. In Europe, inflation data for the euro area was the highlight. The single-currency bloc expanded to 21 countries this year with Bulgaria adopting the currency on January 1. News flow in Asia was dominated by the survey data on the Chinese services industry.